Condition: Liver Cancer, Adult · Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
The study is aimed to test the performance of a simple, easy, reproducible cytofluorimetric assay to complement imaging studies for: * predicting response to immune-therapeutic regimens in HCC in the early phase of treatment, * to rule out pseudo-progression, * to early predict the escape from effectiveness of treatment.
This description comes directly from the study's public registry record.
Laura Gramantieri, MD · 0512142579 · laura.gramantieri@aosp.bo.it
Always discuss trial participation with your own doctor first.
| IRCCS-Azienda Ospedaliero-Universitaria di Bologna | Bologna, Laura Gramantieri, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06777628